Lupin gets USFDA nod for contraceptive pills

Lupin has launched nine products in the US this fiscal and received approvals for 21 from the USFDA

Lupin has secured US Food and Drug Administration’s (FDA) approval to sell the generic version of oral contraceptive Generess tablets in the American market. The tablets have an annual sale of around $90 million and Lupin will benefit as there is only one more company distributing generic version of the drug in the US. Lupin’s stock closed flat at Rs 1,712 on the BSE on Friday.  The approval is important for Lupin, which has a large oral contraceptive business in the US.

Earlier this week, the drug maker launched generic version of Ortho Tri Cyclen Lo tablets which have sales of $ 488 million in the US.

The Ortho Tri Cyclen Lo  represents Lupin’s 16th oral contraceptive launch in the US. The company has filed 37 oral contraceptive products with the FDA till date, Lupin said.

Lupin has launched 9 products in the US this fiscal and received approvals for 21 from the US FDA.